ClinicalTrials.gg
CompletedNCT01810783Updated Mar 27, 2017Results posted

Brexpiprazole in Patients With Schizophrenia

A Phase 3 interventional study of Brexpiprazole in Schizophrenia, sponsored by H. Lundbeck A/S. Completed at 48 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
14th of 28
210 · median 155
Started
2013
with 5 others
Phase 3
16 of 28
none open now
Registered
14th of 28
by date
Lead sponsor
3 of 28
H. Lundbeck A/S

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 14th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 14th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To determine the safety and efficacy of brexpiprazole during long-term treatment.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has completed the lead-in study 14644A.
  • The patient is judged to potentially benefit from 52-week treatment with brexpiprazole according to the clinical opinion of the investigator.
  • The patient agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  • The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14644A.
  • The patient has a unstable illness diagnosed during Study 14644A.
  • The patient, in the opinion of the investigator or according to Columbia-Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
  • The patient has an abnormal or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Drug: Brexpiprazole

Interventions

  • 1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability

    Number of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)

07

Results

Posted Feb 23, 2017

Participant flow

Participant flow — Overall Study
MilestoneBrexpiprazole
Started210
Completed101
Not completed109
Withdrew: Adverse event32
Withdrew: Withdrawal by subject22
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up10
Withdrew: Protocol violation5
Withdrew: Non-compliance with imp4
Withdrew: Adminstrative or other reason(s)23
Withdrew: Enrolled, not treated1

Outcome measures

PrimarySafety and Tolerability

Number of treatment-emergent adverse events (TEAEs)

Time frame:
Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)
Reported as:
Number · TEAEs
Safety and Tolerability
TEAEsBrexpiprazole
Safety and Tolerability337

Adverse events

Collected over Baseline to end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—31/209 (14.8%)47/209 (22.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventBrexpiprazole
SchizophreniaPsychiatric disorders18/209
Psychotic disorderPsychiatric disorders2/209
Suicidal ideationPsychiatric disorders2/209
Social stay hospitalisationSocial circumstances2/209
PregnancyPregnancy, puerperium and perinatal conditions1/112
ColitisGastrointestinal disorders1/209
Peritonsillar abscessInfections and infestations1/209
Humerus fractureInjury, poisoning and procedural complications1/209
Alanine aminotransferase increasedInvestigations1/209
Aspartate aminotransferase increasedInvestigations1/209
Most frequent other events
Most frequent other events
EventBrexpiprazole
Weight increasedInvestigations22/209
HeadacheNervous system disorders18/209
InsomniaPsychiatric disorders17/209

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Brexpiprazole
<=18 years1
Between 18 and 65 years208
>=65 years1
Age, Continuous
Age, Continuous(years)Brexpiprazole
Mean40.89 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole
Female113
Male97
Region of Enrollment
Region of Enrollment(participants)Brexpiprazole
United States50
Ukraine64
Slovakia1
Serbia19
Russian Federation52
Estonia6
Poland9
Romania9
08

Study locations

48 sites
  • US010
    Anaheim, California, United States
  • US020
    Cerritos, California, United States
  • US009
    Escondido, California, United States
  • US022
    Garden Grove, California, United States
  • US018
    Long Beach, California, United States
  • US011
    San Diego, California, United States
  • US021
    Washington, District of Columbia, United States
  • US004
    Kissimmee, Florida, United States
  • US015
    North Miami, Florida, United States
  • US019
    Lake Charles, Louisiana, United States
  • US016
    St. Louis, Missouri, United States
  • US002
    Cedarhurst, New York, United States
  • US005
    Charleston, South Carolina, United States
  • US003
    Austin, Texas, United States
  • US012
    Austin, Texas, United States
  • US001
    Dallas, Texas, United States
  • US013
    Dallas, Texas, United States
  • EE002
    Parnu, Estonia
  • EE001
    Tallinn, Estonia
  • PL002
    Choroszcz, Poland
  • PL005
    Choroszcz, Poland
  • PL004
    Gdansk, Poland
  • RO004
    Brasov, Romania
  • RO011
    Bucharest, Romania
  • RO007
    Bucuresti, Romania
  • RO012
    Bucuresti, Romania
  • RO010
    Iasi, Romania
  • RO006
    Pitesti, Romania
  • RU001
    Arkhangelsk, Russian Federation
  • RU008
    Moscow, Russian Federation
  • RU015
    Rostov on Don, Russian Federation
  • RU002
    Saratov, Russian Federation
  • RU004
    St. Petersburg, Russian Federation
  • RU005
    St. Petersburg, Russian Federation
  • RU013
    St. Petersburg, Russian Federation
  • RS001
    Belgrade, Serbia
  • RS003
    Belgrade, Serbia
  • RS002
    Kragujevac, Serbia
  • RS004
    Novi Knezevac, Serbia
  • SK001
    Liptovsky Mikulas, Slovakia
  • UA012
    Dnipropetrovsk, Ukraine
  • UA004
    Geikivka, Ukraine
  • UA007
    Glevakha, Ukraine
  • UA005
    Kherson, Ukraine
  • UA008
    Kyiv, Ukraine
  • UA009
    Lviv, Ukraine
  • UA002
    Smila, Ukraine
  • UA003
    Vinnytsya, Ukraine
09

References and documents

Publications

  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793. PubMed 35235720 ↗
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan. PubMed 34901863 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2013
First posted
Mar 14, 2013
Start
Jul 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Feb 23, 2017
Last update
Mar 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01810783
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 14, 2013
Start date
Jul 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Feb 23, 2017
Last update
Mar 27, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion